These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32550008)

  • 21. Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences.
    Kähönen J
    Front Psychol; 2023; 14():1104627. PubMed ID: 37388660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature.
    Golden TL; Magsamen S; Sandu CC; Lin S; Roebuck GM; Shi KM; Barrett FS
    Curr Top Behav Neurosci; 2022; 56():35-70. PubMed ID: 35138585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychedelics and virtual reality: parallels and applications.
    Aday JS; Davoli CC; Bloesch EK
    Ther Adv Psychopharmacol; 2020; 10():2045125320948356. PubMed ID: 32922734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mindfulness meditation and psychedelics: potential synergies and commonalities.
    Holas P; Kamińska J
    Pharmacol Rep; 2023 Dec; 75(6):1398-1409. PubMed ID: 37926796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks.
    Pasquini L; Palhano-Fontes F; Araujo DB
    J Psychopharmacol; 2020 Jun; 34(6):623-635. PubMed ID: 32255395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?
    Miceli McMillan R
    Med Humanit; 2022 Sep; 48(3):269-272. PubMed ID: 35074926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective.
    Meling D; Scheidegger M
    Front Psychol; 2023; 14():1100058. PubMed ID: 37077857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
    Kruger DJ; Glynos NG; Fields CW; Herberholz M; Boehnke KF
    J Psychoactive Drugs; 2023; 55(4):420-424. PubMed ID: 36328419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unified model of ketamine's dissociative and psychedelic properties.
    Marguilho M; Figueiredo I; Castro-Rodrigues P
    J Psychopharmacol; 2023 Jan; 37(1):14-32. PubMed ID: 36527355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives.
    Rankaduwa S; Owen AM
    Neurosci Conscious; 2023; 2023(1):niad001. PubMed ID: 37025356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An introduction to psychedelic neuroscience.
    Calvey T; Howells FM
    Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consciousness in active inference: Deep self-models, other minds, and the challenge of psychedelic-induced ego-dissolution.
    Deane G
    Neurosci Conscious; 2021; 2021(2):niab024. PubMed ID: 34484808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).
    Nour MM; Evans L; Nutt D; Carhart-Harris RL
    Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Psilocybin compared with escitalopram for depression].
    Strous JFM
    Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35138714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Henri Michaux's program for the psychedelic humanities.
    Davis O
    Front Psychol; 2023; 14():1152896. PubMed ID: 37275714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting Responses to Psychedelics: A Prospective Study.
    Haijen ECHM; Kaelen M; Roseman L; Timmermann C; Kettner H; Russ S; Nutt D; Daws RE; Hampshire ADG; Lorenz R; Carhart-Harris RL
    Front Pharmacol; 2018; 9():897. PubMed ID: 30450045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.